Press Releases

TRAILBLAZER-ALZ 2 is the second study of donanemab, which showed favorable results in an earlier trial. Washington, DC (March 13, 2021) – Eli Lilly and Company, a leader in Alzheimer’s research for over 30 years, is partnering with the Global Alzheimer’s Platform Foundation® (GAP) to accelerate recruitment services and expand the number of clinical research […]

Statement by GAP President John Dwyer on the results of the Phase 2 trial for Donanemab: We congratulate Eli Lilly on the results of the Donanemab clinical trial showing it significantly slowed the cognitive and functional decline of people with mild Alzheimer’s. This is a major step towards discovery of a disease modifying therapy. Alzheimer’s […]

Statement by Global Alzheimer’s Platform Foundation (GAP) President John Dwyer on today’s announcement that Biogen and Apple are partnering on an observational study to investigate the role Apple Watch and iPhone could play in screening for mild cognitive impairment (MCI):  Today’s announcement by Biogen and Apple marks a significant step on the path to early […]

Global Alzheimer’s Platform Foundation® Chief Science Officer Dr. Richard Mohs testifies at Senate hearing about the Alzheimer’s crisis. Watch the full hearing at United States Senate Committee on Finance. Washington, DC (December 16, 2020) – Today, the Chief Science Officer of the Global Alzheimer’s Platform Foundation® (GAP), Dr. Richard Mohs, testified before the Senate Committee on Finance, […]

Washington, DC (November 25, 2020) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement regarding the Alzheimer’s Disease Data Initiative’s (ADDI) launch of the new Alzheimer’s disease data platform, AD Workbench. “Congratulations on the launch of AD Workbench, by our colleagues at the Alzheimer’s Disease Data Initiative (ADDI). The publicly […]

GAP President John Dwyer says aducanumab offers disease-modifying benefit significantly exceeding current therapies Contact: Pamela Larkin, 408-466-5952, [email protected] Washington, DC (November 6, 2020) – Today, the President of the Global Alzheimer’s Platform Foundation® (GAP), John Dwyer, testified before the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee regarding Biogen’s breakthrough Alzheimer’s drug aducanumab. Given that clinical […]

Contact: Pamela Larkin, 408-466-5952, [email protected] Washington, DC (October 29, 2020) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement regarding C2N Diagnostics’ release of the PrecivityADTM blood test. “Congratulations to the C2N Diagnostics team for successfully developing the first blood test of its kind for Alzheimer’s disease. It will transform […]

The Global Alzheimer’s Platform Foundation® Recognizes Rep. Matt Willhite (D-86) with the 2020 National Citizen Scientist Collaborator Award® Contact: Pamela Larkin – [email protected], 408-466-5952 Contact: Belinda Russel – [email protected], 561-968-2933 West Palm Beach, FL (October 22, 2020) – The Global Alzheimer’s Platform Foundation® (GAP) has recognized State Representative Matt Willhite (D-86) as the honoree of […]

The Global Alzheimer’s Platform Foundation® Recognizes Deborah Whelan with the 2020 National Citizen Scientist Champion Award® Contact: Pamela Larkin – [email protected], 408-466-5952 Contact: Robert Briggs – [email protected], 267-879-1762 Charleston, SC (October 22, 2020) – The Global Alzheimer’s Platform Foundation® (GAP) has recognized Deborah Whelan, a retiree living with Alzheimer’s disease, as the recipient of the National Citizen Scientist Champion Award®. […]

The Global Alzheimer’s Platform Foundation® Has Recognized Dennis Chan for the 2020 National Citizen Scientist Catalyst Award® Contact: Pamela Larkin – [email protected], 408-466-5952 Boston, MA (October 22, 2020) – The Global Alzheimer’s Platform Foundation® (GAP) has recognized Westford retiree Dennis Chan as the honoree of the National Citizen Scientist Catalyst Award®. The Center for Alzheimer […]

The Global Alzheimer’s Platform Foundation® Has Recognized Dr. Collins Lewis for the 2020 National Citizen Scientist Cornerstone Award® Contact: Pamela Larkin – [email protected], 408-466-5952 St. Louis, MO (October 22, 2020) – The Global Alzheimer’s Platform Foundation® (GAP) has recognized St. Louis psychiatrist Dr. Collins Lewis as the honoree of the National Citizen Scientist Cornerstone Award®. […]

Global Alzheimer’s Platform Foundation® National Honorees Include an Advocate with Alzheimer’s Disease, a Doctor with a Family History of Alzheimer’s, a Caregiver and Legislator, and a Retiree in a Clinical Trial Washington, DC (October 22, 2020) – The Global Alzheimer’s Platform Foundation® (GAP) is honoring four Alzheimer’s disease clinical trial volunteers with the 2020 National […]

GAP’s statement: Study cites limited awareness among patients and physicians, anxiety, and lack of quick diagnostics Washington, DC (August 20, 2020) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement regarding a University of Southern California Louis D. Schaeffer Center for Health Policy & Economics white paper, “Key Barriers to […]

Washington D.C. (July 30, 2020) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement regarding recent groundbreaking advances in Alzheimer’s blood test research: “I want to congratulate and thank Dr. Barthélemy, Dr. Horie, Dr. Sato, Dr. Bateman, Dr. Palmqvist, Dr. Janelidze, and Dr. Quiroz on their published research on two […]

Washington D.C. (July 9, 2020) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement regarding Biogen’s submission of its BLA application for Aducanumab with the FDA: “The Alzheimer’s research community is looking forward to a thoughtful review of Aducanumab and ideally, approval by the FDA. This application represents a singular […]

June 2, 2020 The events that spurred the reaction around the country this weekend are painful reminders that injustice remains in our world. At the Global Alzheimer’s Platform Foundation® (GAP), we agree that monumental changes on local and national levels are necessary to address the issues plaguing Black and African American people in our country […]

At a pivotal time in Alzheimer’s research, the GAP Foundation and the Alzheimer’s Drug Discovery Foundation will connect funders with leading innovators Updated on March 26, 2020: The Global Alzheimer’s Platform Foundation (GAP) has announced it is postponing the GAP Innovation Summit that was to be held on May 5, 2020 with our partner, the […]

Three research volunteers given first ever national award for their essential role in combatting the greatest public health crisis for our society in this century Washington, DC (October 23, 2019) –  Today, the Global Alzheimer’s Platform Foundation® (GAP) honors three Citizen Scientists® in recognition of the indispensable role clinical trial volunteers play in the fight […]

First disease-modifying drug in 16 years to be submitted for FDA approval in 2020 ***John Dwyer is available for comment today live from the National Alzheimer’s Summit in Washington, D.C.***  Washington, DC (October 22, 2019) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement on the announcement today […]

Spartan will donate $5 to the GAP Transportation Program from each sale of its rapid APOE test to GAP-Net Research Sites Ottawa, Canada (July 31, 2019) – Spartan Bioscience today announced a partnership with the Global Alzheimer’s Platform Foundation® (GAP) to help recruit possible study participants and accelerate Alzheimer’s clinical trials. Through the partnership, Spartan will donate $5 from […]

During National Citizen Scientist Week, June 17-21, GAP Honors More Than 100 Award Nominees Washington, DC (June 17, 2019) – June 17-21, 2019 is the first ever National Citizen Scientist Week, a time to honor people who volunteer for Alzheimer’s research and inspire hope for new therapies for the disease. To celebrate the contributions of the remarkable volunteers […]

NIA Makes $9 Million Multiyear Grant to Study New Therapeutic Approach, an Orally- Administered Treatment for Alzheimer’s Washington, DC (May 20, 2019) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, today issued the following statement: “The nearly six million Americans with Alzheimer’s and their families deserve for no scientific stone to go […]

Washington, DC (April 10, 2019) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, today issued the following statement: “The Global Alzheimer’s Platform Foundation thanks Commissioner Seema Verma and the Centers for Medicare and Medicaid Services (CMS) for its thoughtful and impactful leadership in implementing policies that will improve Medicare Advantage beneficiaries’ ability […]

GAP President Calls Memory Fitness Programs Through Medicare Advantage “a Game-Changer” Nashville (February 28, 2019)? – Global Alzheimer’s Platform Foundation (GAP) President John Dwyer today announced a roadmap for increasing participation in Alzheimer’s clinical trials by supporting and collaborating with memory fitness supplemental benefit programs offered through select Medicare Advantage plans across the United States. Dwyer […]